Natera shared a post on LinkedIn:
“Today, Natera announced the acquisition of Foresight Diagnostics, a leader in ultrasensitive MRD detection. This combination brings together Foresight’s phased variant technology with Natera’s Signatera platform to further strengthen performance across both solid tumors and hematologic cancers.
Founded in 2020 by physicians and scientists from Stanford University, Foresight has developed MRD assays using an innovative and patented technology, which delivers advanced sensitivity by tracking phased variants. With this approach, Foresight has detected ctDNA at ultrasensitive levels.
The integration of phased variants into Signatera is now available for research use and is expected to launch clinically in 2026. The acquisition also expands our leadership in lymphoma, where Foresight has built a strong scientific foundation, including data that helped drive the inclusion of ctDNA MRD into NCCN guidelines for diffuse large B-cell lymphoma. At this year’s ASH annual meeting, starting tomorrow, our combined teams will present 15 abstracts, underscoring the momentum behind our approach to personalized MRD testing.
We’re excited for the impact this will have on accelerating innovation and improving care for patients worldwide.
We’re also thrilled to welcome Foresight and the company’s incredibly talented team to Natera!”
Adham Jurdi, Sr. Medical Director, Oncology at Natera, shared this post, adding:
“Exciting news this morning!
Foresight Diagnostics transformative phased variants technology will bring further performance enhancements to the gold standard signatera ctdna.
Now let’s generate the data.”
Solomon Moshkevich, President of Clinical Diagnostics at Natera, shared a post on LinkedIn:
“Dear Foresight Diagnostics team, we are thrilled to welcome you to Natera!
Natera and Foresight have a common mission to help cancer patients detect residual disease, avoid unnecessary treatment, and beat cancer.
We have been super impressed with your innovative phased variant technology. We look forward to working with you, to accelerate patient access to this important technology by integrating it into our pan-cancer Signatera MRD platform, now in use by over half of the oncologists in the U.S. and growing fast.
Very proud and thankful for the amazing people at Natera and Foresight, who worked so hard to bring this excellent deal to fruition.”
More posts about Natera.